Prevalence of HCV in β-thalassemia major patients visiting tertiary care hospitals in Lahore – Pakistan

Shahid Nazir, Ahmad Faraz, Naeem Shahzad, Nasir Ali, Muhammd Arman Khan, Mazhar Iqbal, Muhammad Farhan Khan, Toraiz Ahmed, Allah Rakha, Javed Sabzwari

Abstract


Post-transfusion hepatitis (PTH) is majorly caused by hepatitis C virus (HCV). So, recipients of blood/blood products, post-transfusion hepatitis (PTH), renal dialysis patients and intravenous drug users all represent high-risk groups for infection. The aim of the present research was to determine the prevalence of HCV antibody in β-thalassemia major patients visiting different tertiary care hospital in Lahore, Pakistan. HCV seroprevalence and risk factors were studied in 200 β-thalassemia major patients (24 females, 176 males) with different age groups by second generation ELISA during January 2013 to May 2013. Confirmed β-thalassemia major patients from three different tertiary care hospitals were selected with special reference to age, age at the time of diagnosis, frequency of transfusion and present clinical status. Among 200 patients, 82 (41%) were found reactive for HCV antibody with age range of 2 to 18 years with mean age of 8.5 years. This study showed that hemodialysis patients and β-thalassemia sufferers were at higher risk of having HCV infection; the prevalence being 41%.

Full Text:

PDF

References


Pasricha S-R, Frazer DM, Bowden DK, Anderson GJ. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study. Blood, (2013); 122(1): 124-133.

Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood, (2004); 104(1): 34-39.

Li C, Wu X, Feng X, He Y, Liu H, et al. A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood, (2012); 120(19): 3875-3881.

Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion, (2014); 54(4): 972-981.

Shah N, Mishra A, Chauhan D, Vora C, Shah N. Study on effectiveness of transfusion program in thalassemia major patients receiving multiple blood transfusions at a transfusion centre in Western India. Asian journal of transfusion science, (2010); 4(2): 94.

Bresters D, Reesink H, Van der Poel C, Cuypers H, Lelie P, et al. Sexual transmission of hepatitis C virus. The Lancet, (1993); 342(8865): 210-211.

ur Rahman M, Akhtar GN, Qadeer M, Shams T, Usmani A, et al. Safe blood begins with safe donors. Pak J Med Sci July-September, (2003); 19(3): 161-168.

Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood, (2000); 96(10): 3369-3373.

Greenberg PL, Gordeuk V, Issaragrisil S, Siritanaratkul N, Fucharoen S, et al. Major hematologic diseases in the developing world—new aspects of diagnosis and management of thalassemia, malarial anemia, and acute leukemia. ASH Education Program Book, (2001); 2001(1): 479-498.

Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet infectious diseases, (2005); 5(9): 558-567.

Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. Journal of clinical virology, (2005); 34S1-S3.

Kleinman S, Alter H, Busch M, Holland P, Tegtmeier G, et al. Increased detection of hepatitis C virus (HCV)‐infected blood donors by a multiple‐antigen HCV enzyme immunoassay. Transfusion, (1992); 32(9): 805-813.

Rund D, Rachmilewitz E. Thalassemia major 1995: older patients, new therapies. Blood reviews, (1995); 9(1): 25-32.


Refbacks

  • There are currently no refbacks.